| Code | CSB-RA011661MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BA-2101, targeting the interleukin-4 receptor (IL4R), a critical component of type 2 inflammatory signaling pathways. IL4R functions as a cell surface receptor that binds both IL-4 and IL-13, two cytokines central to allergic responses and type 2 immunity. Upon ligand binding, IL4R initiates JAK-STAT signaling cascades that promote IgE class switching, mucus production, and alternatively activated macrophage differentiation. Dysregulated IL4R signaling is implicated in numerous conditions including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
BA-2101 serves as the reference therapeutic antibody that blocks IL4R signaling by preventing both IL-4 and IL-13 from engaging their receptor complexes. This biosimilar provides researchers with a valuable tool for investigating type 2 inflammatory mechanisms, studying cytokine receptor interactions, and exploring therapeutic interventions in allergic and inflammatory disease models. The antibody enables detailed examination of IL4R-mediated pathways in various experimental systems.
There are currently no reviews for this product.